Nitrate/nitrate derivatives vs placebo
Adverse events (3 weeks' · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 8 participantsGRADE not reported
Findings
What do systematic reviews say?
73 questions · 75 findings · 5 reviews
No studies found 25 · 33.3%GRADE not reported 8 · 10.7%Very low 23 · 30.7%Low 17 · 22.7%Moderate 2 · 2.7%High 0 · 0%
Nitrate/nitrate derivatives vs placebo
RCS · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 69 participantsLow
Phosphodiesterase inhibitors vs placebo
Migraine frequency Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted2 studies · 111 participantsLow
Phosphodiesterase inhibitors vs placebo
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted2 studies · 111 participantsVery low
Phosphodiesterase inhibitors vs placebo
Duration of attacks · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 73 participantsLow
Angiotensin‐converting enzyme inhibitors vs placebo
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Phosphodiesterase inhibitors vs placebo
QoL · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Phosphodiesterase inhibitors vs placebo
Adverse events · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted3 studies · 138 participantsGRADE not reported
Phosphodiesterase inhibitors vs placebo
RCS · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted2 studies · 79 participantsLow
Angiotensin‐converting enzyme inhibitors vs placebo
Adverse events (4 to 6‐week · primary Raynaud's phenomenon
Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).
1 finding from 1 review
- RR 1.35 [0.67, 2.73]3 studies · 46 participantsLow
Angiotensin‐converting enzyme inhibitors vs placebo
RCS · primary Raynaud's phenomenon
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Alpha‐blockers vs placebo
Migraine frequency Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 33 participantsGRADE not reported
Alpha‐blockers vs placebo
Severity of attacks · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 25 participantsGRADE not reported
Alpha‐blockers vs placebo
Duration of attacks · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted1 study · 33 participantsGRADE not reported
Levosimendan vs dobutamine
All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).
1 finding from 1 review
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes onlyRR 0.6 [0.36, 1.03]4 studies · 1701 participantsLow
Dopexamine vs dopamine
All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Milrinone vs dobutamine
All‐cause mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Enoximone vs dobutamine
All‐cause short‐term mortality: 1 month · adults with low cardiac output syndrome
It is very uncertain whether enoximone changes all‐cause short‐term mortality: 1 month compared with dobutamine (very low certainty).
1 finding from 1 review
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes onlyRR 0.21 [0.01, 4.11]1 study · 37 participantsVery low
Enoximone vs dobutamine
All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Epinephrine vs norepinephrine
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine (very low certainty).
1 finding from 1 review
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes onlyRR 1.81 [0.89, 3.68]1 study · 57 participantsVery low